NCT03215927View on ClinicalTrials.gov

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

May 30, 2022

Study Completion Date

July 30, 2023

Conditions
MyositisInterstitial Lung Disease
Interventions
DRUG

Abatacept

Abatacept 125mg subcutaneous weekly

OTHER

Placebo

Placebo

Trial Locations (5)

15213

University of Pittsburgh, Pittsburgh

21205

John Hopkins Medical Center, Baltimore

80045

University of Colorado Anschutz Medical Campus, Denver

90211

Cedars-Sinai Medical Center, Beverly Hills

02115

Brigham & Women's Hospital, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Rohit Aggarwal, MD

OTHER

NCT03215927 - Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease | Biotech Hunter | Biotech Hunter